Aiming to drug genetic modifiers, Roche-partnered biotech bags $31M to fuel a drive toward clinic
Over the past year and a half since Scenic Biotech signed its discovery pact with Roche’s Genentech, the partners have expanded the deal twice so that the small Dutch biotech would deploy its target discovery platform in six scientific areas.
Now, Scenic is deciding it’s time to invest on its own pipeline.
Eir Ventures, BioMedPartners and Vesalius Biocapital have led a $31 million financing round for the biotech that it says will fuel its transition into a development-stage company — pushing the lead immuno-oncology program into the clinic while hustling three rare disease candidates toward IND-enabling studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
